The Institute of Neurological Recovery® (INR®) provides medical services to selected patients with selected unmet medical needs.
Appointments at the INR
Consultation and treatment are by appointment only. Phone consultations can be scheduled by calling the INR at +1 (561) 353-9707, Monday through Friday, 9 AM to 6 PM Eastern Time.Referrals to the INR
The INR welcomes referrals from neurologists, geriatricians, internists, family physicians, other health care providers, or family members of patients with selected neuroinflammatory disorders. Please note: INR medical providers utilize PSE for a limited number of off-label indications. INR medical providers do not use PSE for treating Parkinson’s disease, brain tumor, or carpal tunnel syndrome. Individual treatment recommendations are only made following medical evaluation, including history, physical examination, and review of imaging studies. The INR welcomes telephone inquiries from physicians and family members. In particular, the INR encourages telephone inquiry and discussion with an INR medical provider for those patients referred from locations at a geographic distance from Boca Raton, Florida, prior to appointment scheduling. This is recommended especially for those patients who will be flying across country or from overseas for treatment at the INR, due to the special nature of the services provided at the INR, and the unique experience which the INR has performing anti-TNF treatment for neurological disorders.INR Scientific Background
Edward Tobinick M.D., founder of the INR, has advanced scientific investigation of a new therapeutic target for Alzheimer’s disease
Dr. Tobinick was the principal investigator and lead author of the first clinical trial to demonstrate the potential of TNF inhibition utilizing PSE as an Alzheimer’s disease therapeutic, entitled “TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study” (article here) that published in 2006. Dr. Tobinick and his colleagues subsequently published multiple articles detailing the clinical effects of PSE for Alzheimer’s disease, as follows:
- 2007: PSE for treatment of Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2007 Dec;4(5):550-2.
- 2008: Rapid cognitive improvement in Alzheimer’s disease following PSE administration. Edward Tobinick MD, Hyman Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.
- 2008: Rapid improvement in verbal fluency and aphasia following PSE in Alzheimer’s disease. Edward Tobinick MD, H. Gross MD. BMC Neurology. 2008 Jul 21;8:27.
- 2009: Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. Edward Tobinick MD. CNS Drugs. 2009 Sep 1;23(9):713-25.
- 2009: PSE for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today. 2009 Feb;14(3-4):168-77.
- 2010: PSE: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
- 2012: Deciphering the physiology underlying the rapid clinical effects of PSE in Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2012 Jan 1; 9(1):99-109. (Free full-text PDF available here).
Disclaimer: Results vary. Patients may not respond. Treatment is off-label. Please see the Terms of Use.
The INR’s scientific findings have been published in multiple, peer-reviewed medical articles, including articles published in the journals Expert Review of Neurotherapeutics, CNS Drugs, BMC Neurology, Current Alzheimer Research, Clinical Therapeutics, Drug Discovery Today, and Current Medical Research and Opinion. There have been citations to INR publications by hundreds of academic scientists from around the world, including in Nature Clinical Practice Neurology and F1000 Biology. Copyright 2020 INR PLLC, all rights reserved